ArticleAnalytical biochemistry2009
Novel and highly sensitive fluorescent assay for leucine aminopeptidases.
Article in Analytical biochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Study on Single Nucleotide Polymorphism ofFoods (Basel, Switzerland) · 2024Article
- Recent Progress of Activity-Based Fluorescent Probes for Imaging Leucine Aminopeptidase.Biosensors · 2023Review
- Identification of candidate biomarkers for severe adenovirus community-acquired pneumonia by proteomic approach.Heliyon · 2022Article
- Prognostic Value of Preoperative Serum Leucine Aminopeptidases in Hepatocellular Carcinoma Patients Who Underwent Liver Transplantation.Cancer management and research · 2021Article
- Vimentin plays an important role in the promotion of breast cancer cell migration and invasion by leucine aminopeptidase 3.Cytotechnology · 2020Article
- Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers.Oncotarget · 2018Article
- Development of amide-based fluorescent probes for selective measurement of carboxylesterase 1 activity in tissue extracts.Analytical biochemistry · 2017Article
- Leucine aminopeptidase may contribute to the intrinsic resistance of cancer cells toward cisplatin as revealed by an ultrasensitive fluorescent probe.Chemical science · 2016Article
- Overexpression of leucine aminopeptidase 3 contributes to malignant development of human esophageal squamous cell carcinoma.Journal of molecular histology · 2014Article
- Expression of leucine aminopeptidase 3 (LAP3) correlates with prognosis and malignant development of human hepatocellular carcinoma (HCC).International journal of clinical and experimental pathology · 2014Article
- Fluorescence polarization/anisotropy in diagnostics and imaging.Chemical reviews · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
l-Leucine aminopeptidases (LAPs) are implicated in the progress of many pathological disorders and play some regulatory roles in tumor cell proliferation, invasion, and/or angiogenesis. Thus, LAPs not only could become new diagnostic or prognostic biomarkers but also may have potential as novel molecular targets for the treatment of several cancers. Highly sensitive assays are critical for early detection of changes in LAP activity and for screening potent LAP inhibitors. In this study, we developed a novel and highly sensitive fluorescent assay for LAPs based on substituted aminopyridines as fluorescent reporters. This assay was at least 100- and 20-fold more sensitive than commercial colorimetric and fluorescent LAP substrates, respectively. We also showed that this assay was a useful tool for monitoring LAP activities in extracts from cancer cell lines, as well as for the high-throughput screening of inhibitors, which could lead to new cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.